Epidemiology and Genomics Research
CANCER EPIDEMIOLOGY MATTERS E-NEWS
JANUARY 2016
Follow us on Twitter
Funding Opportunity Announcements Funding
International Research Scientist Development Award (IRSDA)(K01)
Application Due Dates: March 2, 2016; March 2, 2017; March 7, 2018
Expiration Date: March 8, 2018
Administrative Supplements for Research on Sex/Gender Differences (Admin Supp)
Application Due Date: March 4, 2016
Expiration Date: March 5, 2016

Applications Due: March 15, 2016

U.S. - China Program for Biomedical Collaborative Research (R01)
Application Due Date: March 17, 2016
Expiration Date: March 18, 2016

Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20)
Application Due Dates: March 18, 2016; January 27, 2017; January 29, 2018
Expiration Date: January 30, 2018
  
Expanding the Encyclopedia of DNA Elements (ENCODE) in the Human and Mouse (UM1)
Application Due Date: March 21, 2016
Expiration Date: March 22, 2016

Characterizing the Functional Elements in the ENCODE Catalog (UM1)
Application Due Date: March 21, 2016
Expiration Date: March 22, 2016

ENCODE Data Coordinating Center (U24)
Application Due Date: March 21, 2016
Expiration Date: March 22, 2016

ENCODE Data Analysis Center (U24)
Application Due Date: March 21, 2016
Expiration Date: March 22, 2016

Genome Sequencing Center for the Gabriella Miller Kids First Pediatric Research Program (U24)
Application Due Date: March 31, 2016
Expiration Date: April 1, 2016

NIH Pathway to Independence Award (Parent K99/R00)
Application Due Dates: Standard dates apply
Expiration Date: May 8, 2016

Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01)
Application Due Dates: Standard dates apply
Expiration DateMay 8, 2019

Grants Policy Announcements GrantsNotices
    
NIH Fiscal Policy for Grant Awards - FY2016

ASSIST Now An Option for All NIH Competing Grant Applications and Some Post-Award Administrative Actions
Job Opportunities Jobs
 
EGRP Fellowships:
  
  


Other NCI Jobs:
  



Tenure Track/Tenure-Eligible Investigator, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics

Upcoming Webinars & Workshops Events
February 1, 2016

February 9, 2016
 
February 10-11, 2016
Washington, DC
 
February 11, 2016
Washington, DC  

February 29, 2016

March 1, 2016
  
March 14-15, 2016
Washington, DC

April 8, 2016
San Francisco, CA

April 16-20, 2016
New Orleans, LA
Note: The AACR Molecular Epidemiology Working Group is accepting applications from molecular epidemiology consortia for meeting space. Applications will be accepted through March 25, 2016. View announcement

May 11-13, 2016
Baltimore, MD

June 21-22, 2016
Rockville, MD

Brain Tumor Epidemiology Consortium Annual Meeting
June 21-23, 2016
Barcelona, Spain
Note: Abstracts for posters or oral presentations are due March 16, 2016
 
Save-the-Date: NCI Workshop on Research Strategies for Nutritional and Physical Activity Epidemiology and Cancer Prevention
June 28-29, 2016
Rockville, MD
 
September 12-14, 2016
Bethesda, MD
Blog Posts Blog
Douglas R. Lowy, M.D.
NCI Cancer Currents Blog

Barry Kramer, M.D., M.P.H. 
NCI Cancer Currents Blog
 
Michael Lauer, M.D.
Open Mike Blog  

Michael Lauer, M.D.
Open Mike Blog  
About EGRP AboutUs
The Epidemiology and Genomics Research Program (EGRP) in the Division of Cancer Control and Population Sciences (DCCPS) funds research in human populations to understand the causes of cancer and related outcomes.

The Program fosters interdisciplinary collaborations, as well as the development and use of resources and technologies to advance cancer research and translation of this research, which serve as the basis for clinical and public health interventions.
Contact Us Contact
Text in graphic_ Research Highlights
2015 Research Highlights from Our Grantees RH

Each year, staff in the Epidemiology and Genomics Research Program (EGRP) nominate and vote for manuscripts published by EGRP grantees that are deemed to have the greatest potential scientific and/or public health impact. The following publications were chosen for inclusion in the  2015 Research Highlights :
 
Breast Cancer 
Colorectal Cancer 
Diet 
Endometrial Cancer
Next-Generation Sequencing 
Lung Cancer  
Pancreatic Cancer  
Congratulations to all our winners! More details about the current and past Research Highlights publications can be found on the EGRP website.
 

NIH's Genomic Data Sharing Policy: Making Sense of Changing Informed Consent Requirements InformedConsent


EGRP-supported investigators often make use of tissues or other samples acquired from humans as byproducts of common clinical procedures that are unrelated to research projects. Staff in EGRP have received several questions in the past few months from extramural investigators about consent requirements for biospecimens under the  NIH's Genomic Data Sharing (GDS) Policy . Thus, in this article, we present information about informed consent requirements under the GDS Policy, and the questions investigators should consider when applying these requirements to their research.

Under the current regulations for the protection of human research subjects, also known as the Common Rule, work with de-identified materials* is not considered human subjects research, and hence de-identified specimens typically can be used without written informed consent from donors for specific research projects. However, the NIH's GDS Policy requires that tissues, samples, or cell lines collected as of the Policy's effective date must have the donor's consent for future research use and broad data sharing, regardless of whether they have been de-identified. This requirement applies to competing applications proposing projects that generate large-scale genomic data submitted to NIH on or after January 25, 2015.

Some key points that EGRP would like investigators to keep in mind include:

  • If the project falls under the GDS Policy, but the biospecimen samples used to generate data were collected before January 25, 2015, the samples would be grandfathered in under the old consent requirements (i.e., current Common Rule standard).
  • If the project falls under the GDS Policy, and the biospecimen samples were collected on or after January 25, 2015, the samples must have consent for future research use and broad data sharing even if the samples have been de-identified.
Investigators who collaborate with other research partners that collect biospecimens, such as a biobank, or participate in sample pooling projects will need to work closely with collaborators to ensure proposed projects comply with the NIH GDS Policy.

Additional information about the GDS Policy is available on a new NCI webpage, including when the policy applies, examples of projects that fall under the policy, exceptions to the policy, and more about informed consent, including a link to sample consent forms available through the National Human Genome Research Institute (NHGRI). Investigators with additional questions may contact EGRP's Charlisse Caga-anan, J.D., for further guidance.

*Note: There is a regulatory definition in the Common Rule for what it means for materials to be "identified," and there is guidance in the Health Insurance Portability and Accountability Act (HIPAA) for what is considered "de-identified." Although it can be argued that DNA can never really be de-identified, the NIH GDS Policy requires genomic data submitted to an NIH-designated repository be de-identified, consistent with Common Rule and HIPAA standards. Additionally, the NIH GDS Policy requires secondary users of the data to agree not to attempt to identify individuals from whom the data or samples were collected.
Large-Budget Grant Applications Require 8 Weeks Advance Notice Before Submission  ARA
The National Cancer Institute (NCI) and the NIH require grant applications with requested budgets of $500,000 or more in subtotal direct costs in any one year to contact the appropriate program staff member and receive approval before submitting proposals to NIH's Center for Scientific Review (CSR).   
  
The  NIH Guide for Grants and Contracts' Notices  NOT-CA-02-029 and  NOT-OD-02-004 state that approval must be sought 6 weeks prior to submitting such applications. However,  approval for applications assigned to the Division of Cancer Control and Population Sciences (DCCPS), of which EGRP is a part, must be sought at least 8 weeks prior to submission to CSR or NCI in order to complete the necessary internal processing.
 
Investigators must follow this policy, speak to the appropriate EGRP Program Director, and respond to requests for information. If advance notice of the proposed research and budget is not approved by DCCPS, CSR will not accept the application, which will result in a delay in consideration until the next submission deadline. This policy applies to new, competing continuation, competing supplement, and amended/resubmitted applications.
 
However, it does not apply to applications submitted in response to Funding Opportunity Announcements (FOAs) with specified budget limits. Investigators should also be aware that approval given to submit a large-budget application is limited to the cycle for which the proposal is submitted.
 
Learn more about the materials required for submitting an Awaiting Receipt of Application (ARA), deadlines, and frequently asked questions.
 

 
Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute | 9609 Medical Center Drive | 4 East, MSC 9763 | Bethesda | MD 20892